BIO
Bio-Rad Laboratories, Inc. Health Care Laboratory Analytical Instruments Russell 3000
$372.18Close
$241.71 – $390.3452-week range
Nov 4, 2026Next report · after the close
Highlights
Strengths
- Near its high 5% below its 52-week high
Cautions
- Trend not confirmed 7 of 8 conditions · under the 50-day
- Results soon Nov 4, 2026, in 3 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
5%
1wk
up 0.6%
price change
1mo
down 1.5%
price change
12-month return
up 22%
market up 11% ·
its own up 6%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
—
price / book
Earnings yield
—
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
up 1%
year on year
EPS growth
up 19%
latest quarter · +973 pts
Sales growth
0%
latest quarter · -1 pts
ROE
up 11%
return on equity
Free cash margin
up 15%
$374.6M FCF
D/E
0.16
long-term debt / equity
Net debt / EBITDA
3.2×
Interest cover
1.0×EBIT / interest
Piotroski tests
Repair signals
- Revenue reaccelerating (-4% then +1%)
Trade setup
ATR%
3.1%
$11.71 a day · 2×ATR $348.77
RS
79 / 99
vs the universe
Trend
7 / 8
under the 50-day
Relative volume
0.7×
vs 50-day average
Up/down volume
1.10
50 sessions
Implied move
—
no option chain · report Nov 4, 2026
Trend template · 7 of 8
- Price above the 50-day average: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Interest is covered, but thinly Earnings before interest cover the interest bill 1.0 times, leaving little room if profits fall.
- Profit not backed by cash Reported profit of $759.9M came with $532.2M of operating cash flow. Profit that cash does not follow is the classic signature of aggressive accounting.
- Gross margin narrowing Gross margin fell from 53.7% to 51.9%. The company is keeping less of each dollar of sales than it did a year ago.
Last reported
Aug 4, 2026
Results reaction
Aug 4, 2026+2% vs market2 sessions after results
Financials
- Gross 52%
- Net 29%
- Free cash 15%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $2.5B | $2.9B | $2.8B | $2.7B | $2.6B | $2.6B |
| Gross margin | 56% | 56% | 56% | 53% | 54% | 52% |
| Operating income | $421.3M | $500.3M | $482.6M | $337.8M | $269.0M | $47.2M |
| Net income | $3.8B | $4.3B | -$3.6B | -$637.3M | -$1.8B | $759.9M |
| Net margin | 150% | 146% | -129% | -24% | -72% | 29% |
| Earnings per share | $126.47 | $140.83 | -$121.79 | -$21.82 | -$65.36 | $27.85 |
| Free cash flow | $476.4M | $535.7M | $81.6M | $218.2M | $289.6M | $374.6M |
| Free cash margin | 19% | 18% | 3% | 8% | 11% | 15% |
| Cash | $662.2M | $470.8M | $434.2M | $403.8M | $488.1M | $529.8M |
| Long-term debt | $12.3M | $10.5M | $1.2B | $1.2B | $1.2B | $1.2B |
| Shareholders' equity | $9.9B | $13.7B | $9.6B | $8.7B | $6.6B | $7.5B |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 4, 2026 | Quarterly ↗ | Jun 30, 2026 | 35d |
| Apr 30, 2026 | Quarterly ↗ | Mar 31, 2026 | 30d |
| Feb 13, 2026 | Annual ↗ | Dec 31, 2025 | 44d |
| Oct 29, 2025 | Quarterly ↗ | Sep 30, 2025 | 29d |
| Jul 31, 2025 | Quarterly ↗ | Jun 30, 2025 | 31d |
| May 1, 2025 | Quarterly ↗ | Mar 31, 2025 | 31d |
| Feb 14, 2025 | Annual ↗ | Dec 31, 2024 | 45d |
| Oct 31, 2024 | Quarterly ↗ | Sep 30, 2024 | 31d |
| Aug 2, 2024 | Quarterly ↗ | Jun 30, 2024 | 33d |
| May 8, 2024 | Quarterly ↗ | Mar 31, 2024 | 38d |
| Feb 16, 2024 | Annual ↗ | Dec 31, 2023 | 47d |
| Oct 27, 2023 | Quarterly ↗ | Sep 30, 2023 | 27d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 4, 2026 | Results · Restructuring · Regulation FD ↗ |
| Apr 30, 2026 | Results · Regulation FD ↗ |
| Apr 24, 2026 | Director or officer change · Shareholder vote ↗ |
| Feb 19, 2026 | Regulation FD ↗ |
| Feb 12, 2026 | Results · Regulation FD ↗ |
| Oct 29, 2025 | Results · Regulation FD ↗ |
| Sep 30, 2025 | Regulation FD ↗ |
| Aug 26, 2025 | Regulation FD ↗ |
| Jul 31, 2025 | Results · Regulation FD ↗ |
| Jul 28, 2025 | Director or officer change · Other events ↗ |
| Jun 30, 2025 | Other events ↗ |
| May 1, 2025 | Results ↗ |